What does Nuevocor do?
Nuevocor is a biotechnology company developing new therapies for genetic cardiomyopathies driven by aberrant mechanobiology, leveraging its proprietary PrOSIA mechanobiology platform to target shared disease pathways.
How much did they raise?
The company raised US$45M in Series B funding, led by Kurma Partners and Angelini Ventures, with participation from EDBI, ClavystBio, Boehringer Ingelheim Venture Fund, Highlight Capital, and SEEDS Capital.
What are their plans for the money?
The funds will be used to support the Phase 1/2 clinical trial of its lead candidate, NVC-001, in patients with LMNA-related dilated cardiomyopathy, potentially accelerating the development of groundbreaking treatments.
What have they achieved so far?
Nuevocor has made significant strides with its IND-stage candidate and enriched its governance by adding experienced board members from Kurma Partners and Angelini Ventures.
